Vanguard Group Inc Cytom X Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,162,302 shares of CTMX stock, worth $5.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,162,302

Previous 4,892,302 5.52%

Holding current value

$5.16 Million

Previous $5.97 Million 2.06%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.12 - $1.51 $302,400 - $407,700	270,000 Added 5.52%	5,162,302 $6.09 Million
Q2 2024 Aug 13, 2024	BUY	$1.21 - $5.13 $42,262 - $179,180	34,928 Added 0.72%	4,892,302 $5.97 Million
Q1 2024 May 10, 2024	SELL	$1.41 - $2.74 $64,252 - $124,859	-45,569 Reduced 0.93%	4,857,374 $10.6 Million
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $17,075 - $23,251	-12,110 Reduced 0.25%	4,902,943 $8.43 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.88 $487,411 - $948,476	329,332 Added 7.18%	4,915,053 $7.42 Million
Q4 2022 Feb 10, 2023	BUY	$1.19 - $1.91 $56,834 - $91,221	47,760 Added 1.05%	4,585,721 $7.34 Million
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $664,723 - $1.06 Million	-540,426 Reduced 10.64%	4,537,961 $6.58 Million
Q2 2022 Aug 12, 2022	SELL	$1.53 - $2.89 $221,083 - $417,602	-144,499 Reduced 2.77%	5,078,387 $9.29 Million
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $306,769 - $537,708	114,895 Added 2.25%	5,222,886 $13.9 Million
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $1.58 Million - $3.02 Million	-408,330 Reduced 7.4%	5,107,991 $22.1 Million
Q3 2021 Nov 12, 2021	BUY	$4.32 - $6.43 $683,579 - $1.02 Million	158,236 Added 2.95%	5,516,321 $28.1 Million
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $33.9 Million - $53.1 Million	5,358,085 New	5,358,085 $33.9 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.4M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cytom X Therapeutics, Inc. Transaction History